selicrelumab: Clinical Trials

3 trials of selicrelumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 terminated. 3 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 1, Recruiting 1, Terminated 1
Phase 23Completed 1, Recruiting 1, Terminated 1

Follow selicrelumab: new trials by email Literature Review of selicrelumab trials Research Report on selicrelumab

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Regorafenib, Atezolizumab, Imprime PGG - Colorectal Cancer
Phase 1 / Phase 2TerminatedHoffmann-La Roche962018-09-272023-11-07
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Capecitabine, Atezolizumab, Ipatasertib - Metastatic Breast Cancer
Phase 1 / Phase 2RecruitingHoffmann-La Roche11322018-03-302026-11-06
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Nab-Paclitaxel, Gemcitabine, Oxaliplatin - Pancreatic Adenocarcinoma
Phase 1 / Phase 2CompletedHoffmann-La Roche3412017-07-052025-11-21

Conditions studied

Breast Neoplasms (1)  ·  Colorectal Neoplasms (1)

Sponsors

Hoffmann-La Roche (3)

Countries

South Korea (3)  ·  United States (3)  ·  Australia (2)  ·  France (2)  ·  Germany (2)  ·  Spain (2)  ·  Israel (1)  ·  Japan (1)  ·  Switzerland (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Results publications

PMID 36940261, PMID 39707623

NIH funding

2017 (2), 2016 (1), 2023 (1)